NCT04041856 is a Phase 1, PHASE2 clinical trial of Povidone Ophthalmic in Adenoviral Keratoconjunctivitis, sponsored by Farabi Eye Hospital.

Who is sponsoring NCT04041856?

NCT04041856 is sponsored by Farabi Eye Hospital.

What drugs are being tested in NCT04041856?

Interventions in NCT04041856: Povidone Ophthalmic.

What condition does NCT04041856 study?

NCT04041856 studies Adenoviral Keratoconjunctivitis.

Is NCT04041856 still recruiting?

NCT04041856 is currently status unknown. Last updated 1 August 2019.

Last reviewed 2019-08-01 · How we verify

NCT04041856

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Povidone-iodine 2% Eye Drop Versus Artificial Tear Drop for Treatment of Adenoviral Keratoconjunctivitis

Status unknown Phase 1, PHASE2 Last updated 1 August 2019

What this trial tests

Phase 1, PHASE2 trial testing Povidone Ophthalmic in Adenoviral Keratoconjunctivitis in 200 participants. Status unknown.

Timeline

23 August 2019

Primary endpoint
22 October 2019

22 November 2019

Quick facts

Lead sponsor	Farabi Eye Hospital
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	23 August 2019
Primary completion	22 October 2019
Estimated completion	22 November 2019

Drugs / interventions tested

Povidone Ophthalmic — full drug profile →

Conditions studied

Adenoviral Keratoconjunctivitis — all drugs for Adenoviral Keratoconjunctivitis →

Sponsor

Farabi Eye Hospital

Who can join

17 and older, any sex, with Adenoviral Keratoconjunctivitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis.
Liu SH, Hawkins BS, Ng SM, Ren M, et al · · 2022 · cited 9× · PMID 35238405 · DOI 10.1002/14651858.cd013520.pub2

Verify or expand the search:

Other trials of Povidone Ophthalmic

Trials testing the same drug.

NCT05287425 — The Effect of Antibiotic Eye Drops on the Nasal Microbiome in Healthy Subjects · Phase 2 · completed

Other recruiting trials for Adenoviral Keratoconjunctivitis

Currently open trials in the same condition.

NCT05123014 — Lenticule Implantation and Autologous Serum New Approach in Treatment of Adenoviral Keratitis Disease · NA · active not recruiting

Other Farabi Eye Hospital trials

Trials by the same sponsor.

NCT03138785 — UVX as an Adjuvant in the Treatment of Fungal Keratitis · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04041856 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Farabi Eye Hospital
Last refreshed: 1 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04041856.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing